Answers are grounded in this paper and cite their sources.
Collaboration between healthcare professionals, patients, and pharmaceutical companies have helped development of novel drugs and a better understanding of diseases [ 1 ]. Meanwhile, proper management of conflicts of interest (COIs) between healthcare sectors and pharmaceutical companies has increasingly become imperative among all healthcare professionals, as it may jeopardize patient-centered care [ 2 ]. In the field of hematology, a wide variety of therapeutic strategies and novel therapies attracted considerable attention from pharmaceutical companies, resulting in intense marketing by pharmaceutical companies. However, little is known about the characteristics and trends of personal payments from pharmaceutical companies to board-certified hematologists in Japan.
No takes yet. Share an insight, caveat, or question.
Kusumi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: